Janus Henderson Group PLC Has $57,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX)

Janus Henderson Group PLC cut its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 99.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,839 shares of the company’s stock after selling 4,781,513 shares during the quarter. Janus Henderson Group PLC’s holdings in Perspective Therapeutics were worth $57,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of CATX. Deerfield Management Company L.P. Series C grew its holdings in Perspective Therapeutics by 4.3% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock worth $9,375,000 after acquiring an additional 120,991 shares during the period. Nicholson Wealth Management Group LLC boosted its position in shares of Perspective Therapeutics by 0.4% during the 4th quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company’s stock valued at $5,134,000 after purchasing an additional 7,000 shares in the last quarter. Affinity Asset Advisors LLC grew its stake in Perspective Therapeutics by 160.0% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock worth $4,147,000 after purchasing an additional 800,000 shares during the period. Northern Trust Corp increased its holdings in Perspective Therapeutics by 2.8% in the fourth quarter. Northern Trust Corp now owns 487,273 shares of the company’s stock worth $1,554,000 after purchasing an additional 13,115 shares in the last quarter. Finally, Walleye Capital LLC lifted its stake in Perspective Therapeutics by 2,526.2% in the fourth quarter. Walleye Capital LLC now owns 475,792 shares of the company’s stock valued at $1,518,000 after buying an additional 457,675 shares during the period. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CATX has been the subject of several recent analyst reports. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Royal Bank of Canada dropped their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, March 27th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $12.50.

Perspective Therapeutics Stock Down 4.8%

Shares of NYSE CATX opened at $2.39 on Monday. Perspective Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $16.55. The firm’s 50-day simple moving average is $2.24 and its 200 day simple moving average is $3.26.

Insider Transactions at Perspective Therapeutics

In other news, CEO Johan M. Spoor bought 22,026 shares of the stock in a transaction dated Friday, March 28th. The stock was bought at an average price of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the acquisition, the chief executive officer now directly owns 59,383 shares in the company, valued at approximately $133,017.92. This trade represents a 58.96% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Robert F. Williamson III purchased 22,192 shares of the company’s stock in a transaction that occurred on Friday, March 28th. The shares were purchased at an average cost of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the transaction, the director now directly owns 70,837 shares of the company’s stock, valued at $160,799.99. This represents a 45.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 115,696 shares of company stock valued at $256,344 over the last ninety days. 3.72% of the stock is currently owned by insiders.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.